Mostrar el registro sencillo del ítem

Artículo

dc.creatorReguera-Ortega, Juan Luises
dc.creatorGarcía-Guerrero, Estefaníaes
dc.creatorPérez Simón, José Antonioes
dc.date.accessioned2024-05-03T12:56:53Z
dc.date.available2024-05-03T12:56:53Z
dc.date.issued2021-10-21
dc.identifier.citationReguera-Ortega, J.L., García-Guerrero, E. y Pérez Simón, J.A. (2021). Current Status of CAR-T Cell Therapy in Multiple Myeloma. Hemato, 2 (4), 660-671. https://doi.org/10.3390/hemato2040043.
dc.identifier.issn2673-6357es
dc.identifier.urihttps://hdl.handle.net/11441/157596
dc.description.abstractCurrent data on CAR-T cell-based therapy is really promising in multiple myeloma, especially in terms of response. In heavily pretreated patients, who have already received proteasome inhibitors, immunomodulatory drugs and monoclonal antibodies, current trials report an overall response rate ranging from 81 to 97% and 45 to 67% of complete remission rates. Data are less encouraging in terms of duration of response, although most recent trials have shown significant improvements in terms of event-free survival, with medians ranging from 8 to 14 months and up to 77% progression-free survival at 12 months with an acceptable toxicity profile. These data will be consolidated in future years and will provide new evidence on the best timing for CAR-T cell therapy. Moreover, new CAR-T designs are underway and will challenge the current results.es
dc.formatapplication/pdfes
dc.format.extent12 p.es
dc.language.isoenges
dc.publisherMDPIes
dc.relation.ispartofHemato, 2 (4), 660-671.
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectMyelomaes
dc.subjectCAR T-cellses
dc.subjectTarget antigenes
dc.titleCurrent Status of CAR-T Cell Therapy in Multiple Myelomaes
dc.typeinfo:eu-repo/semantics/articlees
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.contributor.affiliationInstituto de Biomedicina de Sevilla (IBIS)
dc.relation.publisherversionhttps://www.mdpi.com/2673-6357/2/4/43es
dc.identifier.doi10.3390/hemato2040043es
dc.journaltitleHematoes
dc.publication.volumen2es
dc.publication.issue4es
dc.publication.initialPage660es
dc.publication.endPage671es

FicherosTamañoFormatoVerDescripción
Currents Status...pdf264.6KbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Atribución 4.0 Internacional